Sunir J. Garg, MD, shares his recent experience at the American Academy of Ophthalmology Annual Meeting in San Francisco and highlights two key takeaways. First, Dr Garg explores the underrepresentation of diverse populations in clinical trials related to diabetes, where most participants are White Americans, leading to a need for more inclusive enrollment strategies to better reflect the American population.
Second, Dr Garg reflects on promising data on two recently approved treatments for diabetic macular edema, including a higher-dose version of aflibercept that offers similar visual acuity gains with longer treatment intervals, and the bispecific molecule faricimab, which outperforms standard treatments, especially in patients with worse visual acuity. Dr Garg is enthusiastic about these developments, as they can improve patient quality of life and reduce the frequency of medical visits.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AAO 2023: Advances in Diabetic Macular Edema Treatment and a Focus on Representation in Clinical Trials - Medscape - Nov 09, 2023.
